{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141566,"version":"4.3.3"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health, Australian Government | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1157530"],"award-info":[{"award-number":["GNT1157530"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,1,20]]},"abstract":"<jats:p>\n                    Cefiderocol is a cephalosporin designed to treat multidrug-resistant Gram-negative infections. By forming a chelated complex with ferric iron, cefiderocol is transported into the periplasmic space via bacterial iron transport systems and primarily binds to penicillin-binding protein 3 (PBP3) to inhibit peptidoglycan synthesis. This mode of action results in cefiderocol having greater\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against many Gram-negative bacilli than currently used carbapenems, \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, and cephalosporins.\n                  <\/jats:p>","DOI":"10.1128\/aac.00685-20","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T09:20:22Z","timestamp":1604481622000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible\n                    <i>In Vitro<\/i>\n                    to Cefiderocol, a Siderophore Cephalosporin"],"prefix":"10.1128","volume":"65","author":[{"given":"Delaney","family":"Burnard","sequence":"first","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Robertson","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"},{"name":"Pathology Queensland, Queensland Health, Herston, Queensland, Australia"},{"name":"Forensic and Scientific Services, Queensland Health, Coopers Plains, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Henderson","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"},{"name":"Princess Alexandra Hospital, Queensland Health, Woolloongabba, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Falconer","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Bauer","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Cottrell","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gassiep","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"},{"name":"Department of Infectious Diseases, Mater Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Norton","sequence":"additional","affiliation":[{"name":"Townsville Hospital and Health Service, Townsville, Queensland, Australia"},{"name":"Faculty of Medicine, University of Queensland, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4437","authenticated-orcid":false,"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"},{"name":"Royal Brisbane and Women\u2019s Hospital, Queensland Health, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-0345","authenticated-orcid":false,"given":"Patrick N. A.","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Herston, Queensland, Australia"},{"name":"Pathology Queensland, Queensland Health, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.2.383-416.2005"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00128-14"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2015.8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01636-16"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1204699"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00006-19"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.07.003"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.116"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05517-11"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(08)70002-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00210"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496330"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01405-16"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_19_2","unstructured":"World Health Organization. 2014. Antimicrobial resistance global report on surveillance. http:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky027"},{"key":"e_1_3_3_22_2","volume-title":"FETROJA (cefiderocol) approved by the FDA for treatment of complicated urinary tract infections (cUTI) in adult patients with limited or no alternative treatment options","author":"Shionogi & Co., Ltd","year":"2019","unstructured":"Shionogi & Co., Ltd. 2019. FETROJA (cefiderocol) approved by the FDA for treatment of complicated urinary tract infections (cUTI) in adult patients with limited or no alternative treatment options. Shionogi & Co., Ltd., Osaka, Japan."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_3_24_2","unstructured":"Office of the Commissioner FDA. 2020. FDA approves antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-antibiotic-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated."},{"key":"e_1_3_3_25_2","unstructured":"Pharmacy Practice News Staff. 2020. FDA grants HABP\/VABP indication for Fetroja. https:\/\/www.pharmacypracticenews.com\/FDA-Approvals\/Article\/09-20\/FDA-Grants-HABP-VABP-Indication-for-Fetroja-\/60715?ses=ogst."},{"key":"e_1_3_3_26_2","volume-title":"Cefiderocol (S-649266), a novel siderophore cephalosporin: in vitro activity against biothreat pathogens, poster","author":"Tsuji M","year":"2016","unstructured":"Tsuji M, Jakielaszek C, Marchand CL. 2016. Cefiderocol (S-649266), a novel siderophore cephalosporin: in vitro activity against biothreat pathogens, poster. IDWeek, New Orleans, LA."},{"key":"e_1_3_3_27_2","volume-title":"Performance standards for antimicrobial disk susceptibility tests. CLSI standard M02","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial disk susceptibility tests. CLSI standard M02. 13th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"13"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.007"},{"key":"e_1_3_3_29_2","unstructured":"EUCAST. 2020. Breakpoints for cefiderocol from EUCAST. Addendum (May 20202) to EUCAST breakpoint tables V.10.0. Breakpoints to be included in EUCAST breakpoint tables v 11.0 January 2021. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Cefiderocol_addendum_20200501.pdf."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1380"},{"key":"e_1_3_3_31_2","volume-title":"Correlations between cefiderocol broth microdilution MICs and disk diffusion inhibitory zone diameters among target Gram-negative organisms, poster P0186","author":"Masakatsu Tsuji MH","year":"2018","unstructured":"Masakatsu Tsuji MH, Yoshinori Yamano NK, Daniel F, Sahm RE. 2018. Correlations between cefiderocol broth microdilution MICs and disk diffusion inhibitory zone diameters among target Gram-negative organisms, poster P0186. 28th ECCMID, Madrid, Spain."},{"key":"e_1_3_3_32_2","volume-title":"CLSI. Performance Standards for antimicrobial susceptibility testing. 27th ed, CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. CLSI. Performance Standards for antimicrobial susceptibility testing. 27th ed, CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.012"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed3010027"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00334-4"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3063-z"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx049"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.03.011"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01454.x"},{"key":"e_1_3_3_40_2","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. CLSI guideline M45. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00685-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00685-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:52:10Z","timestamp":1645462330000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00685-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,20]]}},"alternative-id":["10.1128\/AAC.00685-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00685-20","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.26.009134","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2020-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00685-20"}}